Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP Images)
September 1, 2022 12:54 PM EDTUpdated 03:59 PM
Pharma
Coronavirus

Fol­low­ing FDA, CHMP gives thumbs-up on Pfiz­er, BioN­Tech Omi­cron boost­er

Paul Schloesser

Associate Editor

One day af­ter the FDA cleared Pfiz­er’s bi­va­lent boost­er to go af­ter Omi­cron, the phar­ma gi­ant and its part­ners at BioN­Tech are now one step …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times